Powder: -20°C for 3 years | In solvent: -80°C for 1 year
T0070907 是一种有效且特异性的 PPARγ 抑制剂,Ki 值为1 nM,其选择性比 PPARα 和 PPARδ 高 800 倍以上。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 293 | 现货 | ||
10 mg | ¥ 467 | 现货 | ||
25 mg | ¥ 898 | 现货 | ||
50 mg | ¥ 1,690 | 现货 | ||
100 mg | ¥ 2,580 | 现货 | ||
200 mg | ¥ 3,790 | 现货 | ||
500 mg | ¥ 5,910 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 418 | 现货 |
产品描述 | T0070907(IC50=1 nM) , an effective and specific PPARγ inhibitor, with the >800-fold selectivity over PPARα and PPARδ. |
靶点活性 | PPARγ:1 nM |
体内活性 | T0070907 can attenuate the beneficial effects of lipopolysaccharide pretreatment, such as significantly improving renal insufficiency, reducing hepatocyte damage and circulatory failure, and reducing plasma interleukin-1 elevation caused by severe endotoxemia. |
激酶实验 | Ligand Binding Assay: To determine the binding affinity of T0070907 to the PPARs, scintillation proximity assay (SPA) is performed with the following modifications. A 90-μl reaction contains SPA buffer (10 mm KH2PO4, 10 mm KH2PO4, 2 mm EDTA, 50 mm NaCl, 1 mm dithiothreitol, 2 mmCHAPS, 10% (v/v) glycerol, pH 7.1), 50 ng of GST-PPARγ (or 150 ng of GST-PPARα, GST-PPARδ), 5 nm 3H-labeled radioligands, and 5 μl of T0070907 in Me2SO. After incubation for 1 h at room temperature, 10 μl of polylysine-coated SPA beads (at 20 mg/ml in SPA buffer) are added, and the mixtureis incubated for 1 h before reading in Packard Topcount. [3H]Rosiglitazone is used for PPARγ, and [3H]GW2433 is used for PPARα and PPARδ. |
细胞实验 | MTS assay(Only for Reference) |
分子量 | 277.66 |
分子式 | C12H8ClN3O3 |
CAS No. | 313516-66-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 27.8 mg/mL (100 mM)
1eq. HCl: 27.8 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / 1eq. HCl | 1 mM | 3.6015 mL | 18.0076 mL | 36.0153 mL | 90.0382 mL |
5 mM | 0.7203 mL | 3.6015 mL | 7.2031 mL | 18.0076 mL | |
10 mM | 0.3602 mL | 1.8008 mL | 3.6015 mL | 9.0038 mL | |
20 mM | 0.1801 mL | 0.9004 mL | 1.8008 mL | 4.5019 mL | |
50 mM | 0.072 mL | 0.3602 mL | 0.7203 mL | 1.8008 mL | |
100 mM | 0.036 mL | 0.1801 mL | 0.3602 mL | 0.9004 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
T0070907 313516-66-4 DNA Damage/DNA Repair Metabolism PPAR inhibit T 0070907 Inhibitor T-0070907 Peroxisome proliferator-activated receptors inhibitor